VISKEN
LOE ApproachingNDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISKEN is an oral tablet small-molecule NDA approved in 1982 by Novartis. The generic name and mechanism of action are unknown from available data. This is a mature, legacy product approaching loss of exclusivity.
LOE Approaching
Moderate competitive pressure (30/100) suggests stable but challenged market position; skeleton team likely maintains legacy franchise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero open positions linked to VISKEN reflects its mature, legacy status with minimal headcount growth. Career opportunity on this asset is focused on defending market share, managing generic transition, and optimizing remaining exclusivity value. Working here suits professionals seeking stability over growth, or those building defensive portfolio expertise.
Brand Manager
Worked on VISKEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.